Abstract
In preclinical studies, BMY-14802 [α-(fluorophenyl)-4-(5-fluoro-2-pyramidinyl)-1-piperazine-butanol], a potent sigma ligand, exhibited a profile similar to clozapine, an atyplcal antipsychotic agent. Several atyplcal antipsychotics have previously been demonstrated to increase dopamine (DA) metabolism without altering DA release in vivo , suggesting a potential mechanism for their lack of extrapyramidal side effects. BMY-14802 increased DA metabolism and release while clozapine increased DA metabolism but decreased DA release in the mouse. This is the first demonstration of a sigma ligand mediated DA release in vivo . The lack of extrapyramidal side effects, despite the enhanced DA release in vivo after BMY-14802 suggests that the atyplcal profile of clozapine can not be explained by its depressant actions on DA release alone.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.